Shanghai Cell Therapy nets nearly $77m in Series D1 round

Shanghai Cell Therapy nets nearly $77m in Series D1 round

Artist impression of an immune system T-cell.

24 March, 2021

CCB International cell therapy Jiuzhou Venture Shanghai Cell Therapy Group Sun Rock Capital

Printed by Unregistered user on Mon, 08 Dec 2025 23:13:11 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Temasek-backed Chinese cancer biotech firm Gracell files for $100m US IPO

South Korea's SK Group to buy 10% in US-based fuel cell maker Plug Power for $1.5b

Read more from Greater China

Climate Tech & ESG

Chinese firms committed $80b to overseas cleantech investments in past year: report

IDG, others pour over $141m into Chinese new materials maker Xingi